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ABSTRACT 
 
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, or 
amyotrophic lateral sclerosis are defined by the loss of several types of neurons and glial 
cells within the central nervous system (CNS). Combatting these diseases requires a robust 
population of relevant cell types that can be employed in cell therapies, drug screening, or 
patient specific disease modeling. Human induced pluripotent stem cells (hiPSC)-derived 
neural progenitor cells (hNPCs) have the ability to self-renew indefinitely and differentiate 
into the various neuronal and glial cell types of the CNS. In order to realize the potential 
of hNPCs, it is necessary to develop a xeno-free scalable platform for effective expansion 
and differentiation. Previous work in the Brafman lab led to the engineering of a chemically 
defined substrate—vitronectin derived peptide (VDP), which allows for the long-term 
expansion and differentiation of hNPCs. In this work, we use this substrate as the basis for 
a microcarrier (MC)-based suspension culture system. Several independently derived 
hNPC lines were cultured on MCs for multiple passages as well as efficiently differentiated 
to neurons. Finally, this MC-based system was used in conjunction with a low shear 
rotating wall vessel (RWV) bioreactor for the integrated, large-scale expansion and 
neuronal differentiation of hNPCs. Finally, VDP was shown to support the differentiation 
of hNPCs into functional astrocytes. Overall, this fully defined and scalable 
biomanufacturing system will facilitate the generation of hNPCs and their derivatives in 
quantities necessary for basic and translational applications. 
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1.  INTRODUCTION 
1.1  Neurodegenerative Disease and Stem Cells 
Neurodegenerative diseases represent a leading cause of death within the United States 
and are characterized by a loss of neurons and glial cells within the central nervous 
system. The effected region of the brain or nervous system is closely tied to the 
associated condition. Alzheimer’s disease (AD) is typically associated with a loss of 
neurons within the cerebral cortex. Whereas Amyotrophic Lateral Sclerosis (ALS) is 
associated with a loss or dysregulation of upper and lower motor neurons. Without 
effective treatment methodologies these diseases are a significant challenge to clinicians. 
Additionally, the precise mechanisms of these diseases have eluded researchers due to a 
lack of reliable models which can recapitulate all aspects of the associated disease. 
Historically, animal models have been utilized to study aspects of these diseases, one 
such example is the triple transgenic mouse model of AD. Additionally, researchers have 
relied on post-mortem tissue samples. However, animal models fail to completely mimic 
human systems of disease and post-mortem tissue only provides an end-point of disease. 
Stem cell-based therapies may provide a new avenue of treatment for these typically 
robust neurodegenerative diseases. Stem cells have the ability to self-renew indefinitely 
as well as the ability to differentiate into all the cell types of the CNS.  
Stem cells can be more specifically categorized by their differentiation potential. 
Pluripotent stem cells having the ability to differentiate into cell types characteristic of all 
three germ layers. Comparatively, adult stem cells are fate-restricted and are limited to 
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specific cell types. It has been shown that the overexpression of four transcription factors, 
cMyc, Oct4, Sox2, and Klf4 can reprogram somatic cells into what has been termed 
human induced pluripotent stem cells (hiPSCs) (Takahashi and Yamanaka). HiPSCs 
provide a robust source of pluripotent cells useful for research and clinical applications 
without the ethical concerns associated with the isolation of human embryonic stem cells 
(hESCs). Furthermore, it is possible to generate patient specific hiPSCs that may provide 
additional insight into various disease mechanisms. Although hiPSCs offer significant 
potential, their ability to differentiate into all three germ layers poses risks of 
tumorgenicity. A multipotent progenitor such as human neural progenitor cells (hNPCs) 
capable of differentiating into various cell types such as neurons, astrocytes, and 
oligodendrocytes may provide a better clinical solution.  
Neural progenitor cells are generated by directing hiPSCs down a neuroectodermal 
differentiation pathway. HNPCs express markers such as Sox1, Sox2, and Nestin and 
have already demonstrated their usefulness in previous studies. For instance, neural 
progenitor/stem cells have demonstrated some success as a means to deliver small 
molecules in a gene therapy for glioblastomas (Benedetti et al.). HNPCs have also 
demonstrated use in cell therapies to increase neurogenesis and formation of glial cells 
(Lindvall et al.). It has also been preliminary demonstrated that autologous hNPC-based 
cell therapies are less likely to be immunogenic  (Huang et al.).  
1.1.2  Alzheimer’s Disease 
Alzheimer’s disease (AD) represents the most common form of neurodegenerative 
disease, an estimated 5.7 million Americans are currently living with AD (“2018 
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Alzheimer’s Disease Facts and Figures”). Additionally, this number is expected to rise 
dramatically as the baby boom population increases in age. The pathology of AD consists 
of two main pathological hallmarks: extracellular amyloid beta plaques and intracellular 
neurofibrillary tangles. There are two forms of AD, generally distinguished by the time of 
onset and associated risk factors, familial Alzheimer’s disease (fAD) and sporadic 
Alzheimer’s disease (sAD). FAD is a rarer form of the disease resulting in early onset as 
a result on mutations in Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1) or 
Presenilin-2 (PSEN2) genes. SAD is the more common form of the disease and has been 
linked to many genetic risk factors including polymorphisms in the Apolipoprotein E 
(APOE) gene (Giri et al.). In this study, hiPSCs generated from patients who were 
homozygous for the APOE ε4 allele were made into to hNPCs and subsequently 
differentiated into neurons and astrocytes.  
 
Figure 1-1: APP Processing.  Amyloid Precursor Protein is cleaved through a non-amyloidogenic 
pathway by α secretase within the Aβ domain (shown in red). In the amyloidogenic pathway, APP is 
cleaved by β-secretase which will in turn allow for a peptide fragment with the Aβ domain intact. This 
fragment is additionally cleaved by γ-secretase between 38-42 amino acid residues from the by β-secretase 
cleavage site (Toh and Gleeson).  
The amyloid beta plaques that have formed within the extracellular space are likely a 
result of improper processing of its precursor, APP. This is a transmembrane protein that 
is processed by three separate enzymes α-, β- and γ-secretase. With two different 
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pathways, a non-amyloidogenic and amyloidogenic one. In the non-amyloidogenic, APP 
is cleaved by α-secretase, generating soluble amyloid precursor protein alpha (sAPPα).  
This cleavage occurs within the Aβ domain of the precursor, preventing in its 
oligomerization. In the amyloidogenic pathway, APP is first cleaved by β-secretase, 99 
amino acids from the intracellular carboxy terminal of APP, generating a 99 amino acid 
fragment. This fragment containing the intact Aβ domain, is cleaved by γ-secretase 
generating Aβ peptides at varying lengths. With Aβ1-40, being most abundant as well as 
Aβ1-42, which leads to the primary aggregation of amyloid plaques. It is likely due to 
hydrophobicity, that Aβ1-42 it is more prone to fibril formation (Toh and Gleeson) .  
In addition to the presentation of amyloid plaques, an AD patient’s pathology will also 
include neurofibrillary tangles. An abnormally hyperphosphorylated tau protein, due to 
various pathways, will lead to destabilized microtubules and formation of toxic 
neurofibrillary tangles (Gong and Iqbal). The prevailing underlying pathology for the 
cause of AD could be explained through the amyloid cascade hypothesis. This hypothesis 
suggests that increased Aβ1-42 production, possibly through missense mutations in 
PSEN1, PSEN2, and APP, leads to increased Aβ oligomerization and plaques. This in 
turn could be causing activation of microglial and astrocytes or directly impacting 
neuronal survivability. An altered neuronal ionic homeostasis; and oxidative injury 
resulting from synaptic and neuritic injury. This may in turn lead to altered 
kinase/phosphatase activity causing downstream formation of neurofibrillary tangles 
(NFTs). This widespread neuronal dysfunction along with cell death and disruption of 
transmitter efficacy ultimately resulting in dementia (Hardy and Selkoe). HiPSC-based 
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models of AD may allow for the discovery of better therapeutic targets as to date there 
are no effective treatment options.  
1.1.3  Amyotrophic Lateral Sclerosis  
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease which 
primarily effects motor neurons. It is estimated to have a prevalence of  approximately 5 
in every 100,000 people (Julien).  Similar to AD, ALS is typically split between familial 
and sporadic, with familial only accounting for 10% of cases. There have been several 
genes identified in familial forms of ALS including C9ORF72, TARDBP, and SOD1, 
among others. TDP-43, a DNA/RNA binding protein coded for by TARDBP is a 
common phenotype within 97% of patients. TDP-43 is a protein typically found within 
the nucleus and is responsible for many important RNA processing mechanisms. TDP-43 
plays a role in the splicing of many mRNA transcripts as well as the generation of 
microRNAs. Additionally, TDP-43 has shown the ability to stabilize its own mRNA, 
suggesting a mechanism of autoregulation. TDP-43 is of particular importance in cellular 
survival as it is involved in the formation of cytoplasmic stress granules under conditions 
of cellular stress (Scotter et al.).  
Studies have examined the role of TDP-43 as either a gain or loss of function in disease. 
The overexpression of TDP-43 recapitulates disease phenotypes in transgenic mice 
models, suggesting a gain of toxic function in disease (Wils et al.). Initial investigations 
into a loss of function in mice showed embryonic lethality, indicating the importance of 
TDP-43 in early development (Wu, Cheng, Hou, et al.). Conditional and partial knockout 
models did successfully demonstrate that a loss of TDP-43 function, can lead to motor 
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neuron defects, typical of TDP-43 proteinopathy (Wu, Cheng, and Shen). It is likely that 
the disease mechanisms underlying TDP-43 are both a loss and gain of function. Stem 
cell models of ALS will prove useful in better understanding disease mechanisms.  
 
 
Figure 1-2: TDP-43 Proteinopathy and ALS. TDP-43 is a DNA/RNA binding protein responsible for 
important RNA processing mechanisms. Mislocalization of TDP-43 in ALS results in misfolding, 
oligomerization, and ultimately aggregation leading to cytotoxicity within cells. Repeat sequences within 
C9ORF72 lead to sequestration of important RNA processing proteins. (Scotter et al.)  
  
1.2  Limitations Associated with Cell Based Therapies, Disease Modeling and Drug 
Screening  
Although hNPCs have the potential to provide significant benefits in therapeutic and 
research applications there are a number of limiting factors associated with their use. 
Particularly, as it relates to scalability and defined culture conditions. HNPCs are 
historically cultured in 2D plates coated in either Laminin or Matrigel. These substrates 
are both comprised of extracellular matrix proteins derived from animals, typically mice. 
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Animal-derived substrates are expensive, chemically undefined, and subject to significant 
variation between lots. This variation in substrates or culture reagents can contribute to 
differences in experimental outcomes. Additionally, these substrates contain xenogeneic 
components which may be harmful for cells and ultimately make them unsuitable for 
clinical applications.   
Also, it is prohibitively expensive as well as labor intensive to scale up these cultures. 
Recent clinical trials have demanded upwards of 6 billion cells per dose well beyond 
what 2D cultures could reasonable accommodate (Chen et al.). Additionally, 2D 
monolayer cultures are unable to fully recapitulate disease mechanisms found within the 
complex in vivo microenvironment. Current biomanufacturing processes are unable to 
produce the number of cells that will be necessary in clinical therapy development and 
disease modeling. Therefore, in this study a previously engineered, chemically defined 
peptide is utilized within a microcarrier-based bioreactor to produce a number of neurons 
that could more reasonably be used in drug development and disease modeling.  
1.3  Synthetic Substrates 
In order to replace ECMP-based animal derived substrates researchers have developed 
synthetic polymers as well as synthetic peptides. Polymer based substrates have been 
shown to allow for the expansion and differentiation of hNPCs (Tsai et al.). While these 
polymers have been shown to be effective they have limited ease-of-use on a larger scale. 
Synthetic peptides such as vitronectin derived peptide (VDP), a chemically defined 
substrate engineered within the Brafman Lab, are short amino acid sequences which are 
simple to use in order to coat the surfaces of plates to be used in adherent cell culture.  
 8 
1.3.1  Identification of Vitronectin Derived Peptide as a Scalable Substrate for hNPC 
Expansion and Differentiation 
Surrounding cells is a diverse organization of proteins and polysaccharides otherwise 
referred to as the extracellular matrix. These matrix proteins, such as laminin, vitronectin, 
and fibronectin increase cell surface adhesion as well as influence cell fate through 
signaling pathways via surface receptors known as integrins (Prowse et al.). It is possible 
to use this interaction to engineer short peptides which bind these various integrin 
domains as a substitute for undefined ECMP substrates.  
Previously in the lab, a synthetic peptide was rationally designed from the cell binding 
domain of vitronectin, and subsequently referred to as vitronectin derived peptide (VDP) 
(Varun et al.). A library of peptides was designed using the experimentally determined 
integrin expression of hNPCs and screened for their ability to support cell adhesion and 
growth of hNPCs. This led to the identification of four peptides which were assessed on 
whether they could support the long term expansion of hNPCs. Only one of these four 
peptides was shown to maintain the multipotency of hNPCs and not result in presentation 
of neuronal-like morphologies. This peptide was able to demonstrate across multiple cell 
lines the ability to expand hNPCs for at least ten passages comparable to laminin. Cells 
cultured on VDP showed similar morphology and doubling time as compared to laminin. 
HNPCs cultured on VDP also showed similar expression of the three multipotency 
markers SOX1, SOX2, and Nestin, as assessed by qPCR, immunofluorescence, and flow 
cytometry.   
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VDP-coated surfaces were also shown to support the neuronal differentiation of hNPCs. 
Cells were differentiated by removal of EFG and FGF from culture media and addition of 
BDNF and GDNF. QPCR showed no statistically different expression of B3T and MAP2 
between neurons differentiated on laminin versus VDP. Immunofluorescence revealed 
the expression of B3T, - aminobutyric acid (GABA), neurofilamnet-68 (NF-L), and 
MAP2. This overall demonstrates the ability of VDP to support the long term expansion 
and differentiation of hNPCs.  
1.4  Large Scale Culture of hNPCs 
As previously stated, the future clinical and research applications of hNPCs will require a 
significant number of cells. Generating >109 cells is not feasible on 2D tissue culture 
plates, both logistically and financially. It is possible to scale up the culture of hNPCS 
within a microcarrier based bioreactor system.  
1.4.1  Microcarriers  
Microcarriers are small spherical polystyrene beads, ranging in diameter (100-400 um), 
that are capable of supporting the culture of adherent cells. There are several factors that 
influence the efficiency of microcarrier cell attachment including, chemical composition, 
surface topography, degree of porosity and charge density. Several different microcarrier 
compositions have been produced, including dextran matrix, plastic coated with collagen, 
polystyrene, or cellulose (Malda and Frondoza). In a previous study, polystyrene 
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microcarriers were coated in VDP to encourage cell adhesion and subsequent aggregate 
formation (Srinivasan et al.).  
HNPCs can be enzymatically dissociated from 2D tissue culture plates and seeded on 
Microcarriers coated with VDP in Ultra Low Attachment plates. Cells attached to 
microcarriers to form an initial monolayer around the surface as well as form aggregates 
consisting of multiple MCs. A higher surface area-to-volume ratio allowed for a greater 
expansion of hNPCs than in 2D wells of comparable size. Varying initial microcarrier 
and cell densities allowed for up to 8-fold expansion of RiPSC-hNPCs. HNPCs cultured 
on VDP-MC also continued to highly express the multipotency markers SOX1, SOX2, 
and Nestin as shown through immunofluorescence and flow cytometry. 
Following the successful expansion of hNPCs on VDP-MC, it was investigated whether 
this 3D culture system could be used for the differentiation of hNPCs into neurons. Cells 
were differentiated by removal of EGF and FGF2 and addition of BDNF and GDNF for 
18 days and then media containing no factors was used for the remainder of the culture 
duration. RNA sequencing and qPCR analysis of these neuronal cultures revealed 
downregulation of hNPC markers SOX1, SOX2, Nestin and PAX6. This analysis also 
showed high expression of MAP2, MAPT, RBFOX3, and TUBB3, markers of mature 
neurons, as well as increased expression of markers such as DLG4, SNAP25, and SYN1, 
which are associated with formation of functional synapses. Additionally, flow cytometry 
revealed >80% expression of TUBB3 and >50% expression of NEUN. These neurons 
could be enzymatically dissociated and replated on 2D surfaces with high survivability. 
Immunofluorescent staining showed neurons were positive for the pan-neuronal markers 
MAP2, TUBB3, and NEUN as well as the forebrain marker FOXG1. 
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1.4.2  Bioreactors  
While microcarriers do provide an improved scalable tissue culture model they are still 
insufficient in producing the number of cells needed for clinical and research 
applications. This will require the robust and reproducible production of an order of 
magnitude higher number of cells. Microcarrier cultures integrated within a bioreactor 
system have the potential to provide this solution.  There has been the development of 
many different bioreactor systems for use in mammalian cell culture. Four of these 
bioreactors types are represented in figure 1-7 below.   
 
Figure 1-3: Possible Bioreactor Configurations.  (A) Spinner flask (B) Rotating wall vessel bioreactor 
(C) Wave bioreactor (D) Hollow fiber bioreactor (Schaffer et al.)  
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Spinner flasks (Figure 1-7A) are one of the more common bioreactors used in suspension 
based cultures. They rely on an impeller which imparts rotation into cell suspension and 
allows for better diffusion of nutrients, however this can lead to high levels of shear stress 
within the reactor. Rotating wall vessels (RWV) (Figure1-7B) rely on a semipermeable 
membrane for oxygenation and were designed to simulate microgravity, resulting in a 
system with relatively low shear by comparison. Spinner flasks have been shown to 
support the generation of 3D stem cell derived -cells (Millman et al.). RWV bioreactors 
have been used in the culture of various cell types ranging from extravillous trophoblast 
cells (Zwezdaryk et al.), vaginal epithelial cells (Hjelm et al.), and also retinal organoids 
(DiStefano et al.).  
In this study, a RWV bioreactor was chosen to be integrated with polystyrene 
microcarriers coated in VDP and was investigated for its ability to support the large scale 
expansion and differentiation of  hNPCs. This system is able to provide a physiologically 
relevant low shear environment for the 3D culture of hNPCs.  
 
  
 13 
2.  MATERIALS AND METHODS 
2.1  HiPSC Culture  
2.1.1  HiPSC Maintenance  
All hiPSCs were cultured on Matrigel (Corning) coated plates. SAD- and NDC-hiPSC 
were cultured in Essential 8 Medium (E8) (1x DMEM-F12, 1% (v/v) 
Penicillin/Streptomycin, 543 ug/mL NaHCO3, 64 ug/mL L-Ascorbic acid-2-phosphate, 
140 ng/mL Sodium selenite, 10.7 ug/mL Transferrin, 20 ug/mL Insulin, 100 ng/mL 
FGF2, and 2 ng/mL TFGB). While, fALS-hiPSCs were cultured in either mTeSR1 
(Stemcell Tech) or a solution of 50% mTeSR1 and 50% E8. SAD- and NDC-hiPSC were 
routinely passaged in Accutase, resuspended in E8 with 5 uM Rho Kinase inhibitor, and 
seeded on Matrigel coated 6-well plates. FALS-hiPSCs were initially cultured in a 
medium of only mTeSR1 and were gradually transitioned to 50% E8. FALS-hiPSCs were 
routinely passaged in Accutase, resuspended in either of the pluripotency medias 
previously described with 5 um Rho Kinase inhibitor, and seeded on Matrigel coated 6-
well plates.  
2.1.2  Neural Induction of hiPSCs  
To induce neural fate, hiPSCs were expanded to 80% confluency. Media was aspirated 
from plate and 1.5 mL of ReLeSR (Stemcell Tech) was added to each well. Cells were 
incubated with ReLeSR for 30 seconds at room temperature. ReLeSR was gently 
aspirated and plate was incubated at 37C for 5 minutes. Appropriate culture media was 
added to each well to lift small colonies off of plate. HiPSC colonies were resuspended in 
pluripotency media with 5 uM Rho Kinase inhibitor and placed in a 6-well Ultra Low 
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Adhesion plate on an orbital shaker with agitation (95 rpm). Cells were allowed to 
aggregate for 48 hours and form embryoid bodies. After 48 hours, three fourths of media 
was changed to Neural Induction Media (1x DMEM-F12, 0.5% (v/v) N2 supplement, 1% 
(v/v) B27 supplement, 1% (v/v) GlutaMAX, 1% (v/v) Penicillin/Streptomycin) with 0.2 
ug/mL Noggin and 6.25 uM Dorsomorphin.  
Embryoid bodies were cultured in NIM for an additional 6 days with half media changes 
each day. On day 6, the media and Embryoid bodies were transferred to a 50 mL conical 
and suspended in more NIM containing 5 uM Rho Kinase inhibitor. Embryoid bodies and 
media were transferred to a Matrigel coated 6-well tissue culture treated plate.  
After 48 hours, half media changes were performed each day. After an additional 5 days, 
media was aspirated and cells were incubated in Accutase for 5 minutes at 37 C. Cells 
were gently removed from plate using p1000 micropipette and transferred to a 15 mL 
conical. Neural Expansion Media (1x DMEM-F12, 0.5% (v/v) N2 supplement, 1% (v/v) 
B27 supplement, 1% (v/v) GlutaMAX, 1% (v/v) Penicillin/Streptomycin) with 30 ng/mL 
EGF and 30 ng/mL FGF2 was added to conical to deactivate Accutase. Cell suspension 
was centrifuged at 200xg for 5 minutes and cell pellet was resuspended in NEM with 5 
uM Rho Kinase inhibitor. Cells were seeded on a PLO/Ln coated plates. The plates were 
first coated with poly-L-ornithine (PLO) (4 ug/mL) solution and incubated at 37 C 
overnight and washed twice with 1x DPBS. The plates were then coated with mouse 
laminin (Ln) (4 ug/mL) and incubated at 37C overnight and were washed twice at with 
1x DPBS before use.  
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2.2  HNPC Culture  
hNPCs were cultured on PLO/Ln coated tissue culture treated plates coated as previously 
described. HNPCs were plated on PLO/Ln plates at 1-1.5 x 104 cells/cm2 in Neural 
Expansion Media with Rho kinase inhibitor (Y-27632) to aid single cell survival. Cells 
were routinely passaged upon reaching 80% confluency. Cells were incubated in 
Accutase for 5 minutes at 37C. After which NEM was added to plate to deactivate 
Accutase. Suspension was transferred to 15 mL conical and centrifuged at 200xg for 5 
minutes. Cells were resuspended in NEM with 5 uM Rho Kinase inhibitor to aid single 
cell survival. Cells were plated as described above.  
2.3  Astrocyte Culture 
HNPCs were seeded on either PLO/Ln or VDP coated plates. These cells were cultured 
in Neural Expansion Media for 24 hours and then media was changed to Astrocyte 
Medium (ScienCell) with 10 ng/mL CNTF, 10 ng/ml BMP4, and 10 ng/mL NRG-1. Cells 
were routinely passaged using Accutase similar to methods described above upon 
reaching 80% confluency. After 50 days within differentiation media cells were expanded 
and used for astrocyte marker expression analysis and functional characterization assays.  
2.4  Microcarrier Culture 
2.4.1  Microcarrier Coating 
Tissue culture treated polystyrene Enhanced Attachment Microcarriers (Corning) were 
coated with either PLO/Ln or Vitronectin Derived Peptide (VDP). To coat in PLO/Ln 
microcarriers were suspended in a solution of PLO (4 ug/mL) and incubated at 37C 
overnight. Microcarriers were gently washed twice with 1xDPBS and the resuspended in 
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a mouse laminin solution (4 ug/mL) and incubated at 37C overnight. Prior to use in 
culture microcarriers were washed once with 1xDPBS and once with appropriate cell 
culture media. To coat with VDP microcarriers were suspended in a 0.5 mM solution of 
the synthetic peptide and incubated at 37C for 48 hours. Prior to use in culture 
microcarriers were washed once with 1xDPBS and once with appropriate cell culture 
media.  
2.4.2  HNPC Culture on Microcarriers 
HNPCs cultured on PLO/Ln tissue culture treated plates as described above were 
dissociated into a single cell suspension and resuspended in NEM containing 5 uM Rho 
kinase inhibitor. Cells were seeded at 1.5 x106 cells/well with 1mg/mL of PLO/Ln or 
VDP microcarriers. Plates were incubated for 12 hours with half final culture volume in 6 
well Ultra Low Attachment plates to encourage optimal attachment. Following 12 hours, 
additional media containing Rho kinase inhibitor was added to wells and plate was placed 
on an orbital shaker with agitation set to 95 rpm. After 24 hours following initial seeding 
of cells on microcarriers, three fourths of media was changed and half of media was 
changed each day following.  
Upon reaching confluency, microcarrier-aggregates and cell media were transferred to a 
15 mL conical and centrifuged at 200xg for 3 minutes. Without disturbing aggregates, 
media was removed and the aggregates resuspended in Accutase. Then this solution was 
transferred to 6-well Ultra Low Adhesion plates and placed within incubator at 37C for 
3 minutes on static and an additional 5 minutes on an orbital shaker with agitation set to 
95 rpm. Following agitation NEM was added to wells to deactivate the Accutase and 
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gently pipetted up and down to allow cell detachment from microcarriers. This cell 
microcarrier suspension was passed through a 40 um cell strainer to remove microcarriers 
from cell suspension. Cells were centrifuged at 200xg for 5 minutes and resuspended in 
NEM with 5 uM Rho kinase inhibitor. Cells were seeded on freshly coated microcarriers 
as described above.  
2.4.3  Neuronal Differentiation on MCs 
HNPCs were expanded on microcarriers for 3-4 days as described above and then three 
fourths of media was changed to Neural Differentiation Media (1x DMEM-F12, 0.5% 
(v/v) N2 supplement, 1% (v/v) B27 supplement, 1% (v/v) GlutaMAX, 1% (v/v) 
Penicillin/Streptomycin) with 20 ng/mL BDNF and 20 ng/mL GDNF. Cells were 
cultured in this media, with half media changes each day. After 18 days, media was 
switched to Neural Base Media (1x DMEM-F12, 0.5% (v/v) N2 supplement, 1% (v/v) 
B27 supplement, 1% (v/v) GlutaMAX, 1% (v/v) Penicillin/Streptomycin) for the 
remainder of culture.  
2.5  Bioreactor Culture  
2.5.1  HNPC Expansion in RWV Bioreactor 
Synthecon 55 mL STLVs were prepared according to manufacturer’s instructions. Prior 
to initial use the vessel was dismantled and immersed in a mild detergent for one hour 
and then rinsed using Milli-Q water. The vessel was soaked in Milli-Q water overnight 
and allowed to dry before being autoclaved at 121C for 20 minutes. Prior to each 
experimental use the vessel was rinsed clean with Milli-Q water and then autoclaved as 
described above.  
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HNPCs were cultured on microcarriers for a single passage prior to use in bioreactor. A 
single cell suspension was obtained from 6-well Ultra Low Adhesion plates as previously 
described. HNPCs were seeded within the bioreactor at 2 x 107 cells per vessel with 10 
mg/mL of enhanced attachment microcarriers coated in either PLO/Ln or VDP as 
described previously. Vessel was filled completely with media and all bubbles were 
removed using syringe ports. Vessels were initially spun at a rate of 8-10 rpm and along 
with formation and enlargement of aggregates, the rpm was increased. 
Samples were taken from the fill port each day of expansion for phase contrast imaging 
and in order to obtain cell counts.  To take samples, 30 mL of media was removed and 
the cell-microcarrier aggregates were gently mixed until thoroughly dispersed within 
remaining 25 mL media volume. Two samples of approximately 5 mL were taken 
through the fill port and transferred to a 6 well Ultra Low Adhesion plate for imaging. 
Cells were then stained with Propidium Iodide to assess cell viability.   
Upon reaching confluency, aggregates and media were transferred to 50 mL conicals. 
Following centrifugation and aspiration of the media cells were resuspended in Accutase. 
Aggregates were transferred to a 6 well Ultra Low Adhesion plate and incubated at 37C 
for 10 minutes with no agitation. Following incubation media was added to the plate to 
inactivate Accutase. Cells were separated from microcarriers using 40 m cell strainers. 
Cells were then centrifuged at 200xg for 5 minutes and suspended in appropriate volume 
of media for either cell counting or use in other assays. 
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2.5.2  Neuronal Differentiation in RWV Bioreactor 
For neuronal differentiations in bioreactor, hNPCs were seeded on microcarriers and 
expanded for 4 days in Neural Expansion Media. Following expansion 45 mL of media 
was replaced with Neural Differentiation Media (1x DMEM-F12, 0.5% (v/v) N2 
supplement, 1% (v/v) B27 supplement, 1% (v/v) GlutaMAX, 1% (v/v) 
Penicillin/Streptomycin) with 20 ng/mL BDNF and 20 ng/mL GDNF. Cells were 
cultured within this media for 18 days after which Neural Base Media (1x DMEM-F12, 
0.5% (v/v) N2 supplement, 1% (v/v) B27 supplement, 1% (v/v) GlutaMAX, 1% (v/v) 
Penicillin/Streptomycin) was used for the remaining duration of culture. Cells were 
allowed to differentiate for at least 30 days before being used in assays. Cells were either 
dissociated from microcarriers as previously described or were plated for use in 
immunofluorescence imaging.  
2.6  QPCR  
RNA was isolated from cells using a Nucleospin RNA kit (Macherey Nagel). cDNA was 
synthesized from 1 ug of the isolated RNA using iScript Reverse Transcription Supermix 
(Bio-Rad). QPCR was performed using iTaqTM Universal SYBR Green Supermix (Bio-
Rad) and the primers listed in Table 1 on a CFX384 TouchTM Real-Time PCR Detection 
System. The reaction was performed with an initial 2 minute elevation to 95C, followed 
by 40 cycles at 95C for 5 seconds and 60C for 30 seconds. 18s rRNA levels were used 
as an endogenous control and the gene expression was quantified by using a Ct 
methodology.  
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2.7  Flow Cytometry  
2.7.1  Fixed Cell Staining 
Cells were dissociated from either plates or microcarriers as previously described. The 
cells were then washed once with stain buffer (BD Biosciences). The cells were first 
fixed using BD Cytofix fixation buffer at room temperature for 30 minutes. Cells were 
then washed twice with stain buffer and permeabilized using BD Phosflow Perm Buffer 
III at 4C for 30 minutes. Following permeabilization, cells were washed twice with stain 
buffer and stained using conjugated antibodies as listed in table 3 at 4C overnight. Cells 
were washed twice and resuspended in stain buffer and analyzed with Accuri C6 Flow 
Cytometer (BD Biosciences).  
2.7.2  Live Cell Staining 
For propidium iodide staining, live cell suspension was washed once with 1xDPBS and 
resuspended in stain buffer. Cells were stained with 2 mg/mL propidium iodide for 1-2 
minutes at room temperature protected from light and were analyzed on Accuri C6 Flow 
Cytometer (BD Biosciences).  
For surface marker staining, cells were washed once and resuspended in 1xDPBS. The 
cells were stained for 1 hour at 4C protected from light. Cells were next washed twice 
and resuspended in 1xDPBS and analyzed with Accuri C6 Flow Cytometer (BD 
Biosciences).  
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2.8  Immunofluorescence 
2.8.1  2D Cultured Cell Staining  
Cells were seeded on PLO/Ln or Matrigel coated 12 well plates and incubated for at least 
24 hours not allowing the cells to become more than 50% confluent. Culture media was 
aspirated and cells were fixed using BD Cytofix fixation buffer at room temperature for 
30 minutes. Wells were then washed twice with 1xDPBS. Cells were then permeabilized 
using BD Phosflow Perm Buffer III at 4C for 30 minutes. After permeabilization, cells 
were stained with primary antibodies as described in table 3 at 4C overnight. Cells were 
then washed twice with 1xDPBS and stained with secondary antibodies as described in 
table 3 at room temperature for 2 hours. Cells were washed twice with 1xDPBS and 
stained with Hoescht 33342 at a dilution of 1:5000 for 10 minutes. Cells were then 
washed twice with 1xDPBS and imaged using fluorescent microscope.  
2.8.2  Plating Microcarriers 
Neuron-microcarrier aggregates were carefully transferred from suspension culture to 15 
mL conical using serological pipette. Aggregates were allowed to settle at bottom of 
conical and media was carefully removed. Accutase was added to conical and incubated 
at 37C. Aggregates were mechanically dissociated into smaller aggregates by gently 
pipetting up and down. Neural Base Media was added to deactivate Accutase and conical 
was centrifuged at 200xg for 5 minutes. Smaller aggregates were resuspended in NBM 
and plated on either Matrigel coated plates or Matrigel coated plates with astrocytes. 
Microcarrier aggregates remained in culture for approximately 7 days to allow for 
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neurons to spread from aggregate. At which point, the cells were fixed, permeabilized 
and stained as described previously.  
2.9  ELISAs 
2.9.1  IL-6 
Cells were seeded on a 24 well plate at 100k cells per well and allowed to attach and 
expand for 24 hours. The media was then changed to either NEM or Astrocyte Media 
containing either 25 ug/mL or 50 ug/mL of lipopolysaccharide (LPS) (eBiosciences). 
Additionally, a saline control was used for comparison. After treatment for 24 hours the 
conditioned media was collected and stored at -20C until use. The commercially 
available IL-6 Human Instant ELISA Kit (Invitrogen) was used to measure inflammatory 
response due to LPS according to the manufacturer’s protocols. Samples were incubated 
in wells pre-coated with monoclonal antibody for Human IL-6, conjugated antibody to 
IL-6 and Streptavidin-HRP for 3 hours at room temperature with shaking (400 rpm). The 
wells were then washed four times and incubated with TMB for 10 minutes at room 
temperature protected from light. A stop solution was added and the absorbance 
immediately read at 450 nm. 
2.9.2  ApoE 
Cells were seeded on a 12 well plate at 100k cells per well and allowed to attach and 
expand for 48 hours. The cell culture media was changed once at 24 hours. After an 
additional 24 hours the media was collected and concentrated 8-10X. Concentrated media 
samples were stored at -80C until use. Cells were lysed in 0.1% TBST with protease 
inhibitors and the lysate was collected and stored at -80C until use. A Bradford assay 
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was used to determine the total protein. The commercially available Apolipoprotein E 
Human ELISA Kit (Thermo Fisher) was used to assess level of ApoE in the concentrated 
media. Samples were incubated in wells pre-coated with antibody specific to human 
ApoE for 2.5 hours at room temperature with shaking (200 rpm). The wells were washed 
four times and then incubated with a biotinylated antibody for 1 hour with shaking (200 
rpm). The wells were then washed four times and incubated with Streptavidin-HRP 
reagent for 45 minutes at room temperature with shaking. The wells were again washed 
four times and then TMB substrate was added to each well and the plate was developed at 
room temperature protected from light. A stop solution was added and absorbance was 
measured at 450 nm.  
2.10  Glutamate Uptake Assay  
To assess glutamate uptake cells were seeded in a 12 well plate at 100k cells per well. 
After 24 hours cells were treated with glutamate in Hank’s Buffered Salt Solution 
(HBSS) with varying concentrations. Samples were taken from the wells at three time 
points: 0, 1, and 2 hours. A commercially available Glutamate Assay Kit (Sigma) was 
used, according to manufacturer’s protocols, to determine the levels of glutamate within 
the supernatant. Samples were incubated with a reaction mix comprised of an assay 
buffer, developer, and enzyme mix for 30 minutes at 37C protected from light. 
Following incubation, the absorbance was then measured at 450 nm. 
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3.  RESULTS 
3.1  Generation and Characterization of hNPCs. 
Previous work has shown a robust and efficient means of differentiating human induced 
pluripotent stem cells into neural progenitor cells (hNPCs) by modulation of TGF- 
signaling (Brafman). This protocol has been used within the lab to generate stable hNPC 
lines from a number of healthy and disease patient samples. In particular, this protocol 
was adapted to generate hNPCs from two different familial amyotrophic lateral sclerosis 
(fALS) patient lines: 034 and A4V. Three fALS-hiPSC lines were received from the 
Sattler lab at Barrow Neurological Institute. These lines have three different mutations 
which have been identified as genetic risk factors in fALS. The related gene mutations 
associated with each line can found in table 1. 034- and A4V-hNPCs were characterized 
by their expression of the markers SOX1, SOX2, and Nestin. As compared to their 
respective hiPSCs, 034- and A4V-hNPCs showed upregulation of the markers SOX1 and 
Nestin by RT-qPCR (Figure 3-1B). Additionally, flow cytometry analysis revealed 
greater than 99% expression of these three markers in fALS-hNPCs (Figure 3-1C). In 
addition, immunofluorescent staining confirmed the expression of relevant hNPC 
markers (Figure 3-1D).  
 25 
 
Figure 3-1: Generation of hNPCs from patient derived fALS-hiPSCs.  (A) Representative phase 
contrast images of A4V- and 034-hiPSCs that have been passaged using Accutase (scale bar =1000 um) (B) 
Quantitative PCR analysis for expression of hNPC markers SOX1, SOX2, and Nestin as compared to avg. 
hiPSC expression (mean ± S.E.M) (Student’s t-test, * p<0.01) (c) Flow cytometry analysis for expression 
of SOX1, SOX2 and Nestin in hNPC lines. (D) SOX1, SOX2, and Nestin immunofluorescence in 034- and 
A4V-hNPCs (034, scale bar = 100 um; A4V, scale bar = 200 um).  
 
More broadly the lab has generated numerous neural progenitor cell lines from different 
patient samples. These cell lines will be useful for the study of relevant disease 
mechanisms including familial Alzheimer’s disease, sporadic AD, as well as familial 
amyotrophic lateral sclerosis. Information pertaining to these lines is summarized within 
table 1 below.  
 
 
  
 26 
Cell Line Patient’s Diagnosis  Mutation 
160-sc1 Sporadic AD APOE E4/E4 
384-sc4 NDC APOE E4/E4 
414-sc8 NDC APOE E4/E4 
188-sc18 Sporadic AD  APOE E4/E4 
TGEN 10_08 NDC N/A 
HVRD-001A Familial AD  APPV717I 
CS40iFAD-n1 Familial AD  PSEN1A246E 
UCSD239iAPP2-1 Familial AD APPdp 
JH034 Familial ALS C9orf72 
SODA4V Familial ALS SOD1 
Table 1: Summary of Patient Derived hNPCs 
3.2  Expansion of hNPCs on VDP-MC in RWV Bioreactor 
Previously, VDP was identified as a substrate capable of supporting the long-term 
expansion and maintenance of hNPCs derived from pluripotent stem cells. Additionally, 
it has been shown that polystyrene enhanced attachment microcarriers coated in VDP 
(VDP-MC) can support the long-term culture of hNPC. It was investigated whether this 
could be successfully integrated within a RWV bioreactor to increase the scale of the 
culture further. RiPSC-hNPCs were seeded on VDP-MC and cultured within the 
bioreactors for at least 6 days. This culture system was able to support the expansion of 
RiPSC-hNPCs on VDP-MC to over 200 million live cells (215.94 ± 52.60 x 106 cells; 
n=4) (Figure 3-2D). In addition, flow cytometry and immunofluorescence demonstrated 
high levels of expression for the NPC markers, SOX1, SOX2 and Nestin (Figure 3-2C 
and E).   
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Figure 3-2: Expansion of RiPSC-hNPCs on VDP-MC in RWV Bioreactor. (A) Image of four vessel 
bioreactor configuration within tissue culture incubator. (B) Representative phase contrast image of NDC-
hNPCs cultured on VDP-coated microcarriers in RWV. (C) Immunofluorescent images of SOX1, SOX2, 
and Nestin in hNPCs cultured on VDP-MC in RWV. (D) Live cell count of NDC-hNPCs expanded in 
bioreactors (n=4). (E) Flow cytometry analysis of SOX1, SOX2, Nestin and propidium iodide staining in 
NDC-hNPCs. (adapted from Srinivasan et al.) 
 
3.3  Neuronal Differentiation of hNPCs in RWV Bioreactor  
Following the confirmation of a reproducible hNPC expansion within the bioreactors. 
Previously developed cortical neuronal differentiations protocols were adapted for use in 
the bioreactor as described within the methods. RiPSC-hNPCs were seeded on VDP-MC 
and expanded for 3-4 days within the bioreactor, then three fourths of the media was 
changed to Neural Differentiation Media (NDM). Aggregates were cultured within the 
bioreactor in this media for 18 days, at which the media was replaced with NBM 
containing no growth factors. After at least 30 days of differentiation, these cells were 
assessed for their expression of mature neuronal markers. Differentiation of RiPSC-
hNPCs within the bioreactors allowed for the generation of over 130 million neurons 
(133.25± 47.98 x 106 neurons; n=3) (Figure 3-4A). Further analysis of these cultures by 
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RNA-seq revealed high levels of gene expression associated with mature neurons such as 
MAP2, MAPT, RBFOX3, TUBB3. Additionally, RNA-seq showed the expression of 
markers typical of cortical/forebrain neurons (e.g. ASCL1, CTIP2, EMX1/2, LHX9, 
TBR1) as well as, genes associated with functional synapse formation (e.g. SNAP25, 
SYN1, SYP) (Figure 3-4D). It was also confirmed using flow cytometry that cells were 
expressing TUBB3 and NEUN (Figure 3-4B).  Finally, aggregates that were plated on 2D 
plates coated in Matrigel were confirmed to be expressing the markers MAP2, TUBB3 
and FOXG1 through immunofluorescent staining (Figure 3-4E).  
 
Figure 3-3: Cortical Neuronal Differentiation of NDC-hNPCS on VDP-MC in RWV Bioreactors. (A) 
Live cell count of NDC-NPC derived cortical neurons obtained through PI staining (n=3). (B) Flow 
cytometry analysis for TUBB3, NEUN and PI in differentiated cells. (C) Quantitative PCR for several 
neuronal and cortical markers in NDC neurons on VDP-MC relative to expression in hNPCs. (D) RNA 
sequencing was performed comparing the expression profiles of hNPCs and cortical neurons.  Average 
values of FPKM from four independent samples are shown. Genes that had an altered expression with FDR 
<0.001 and more than 2-fold changes were considered significantly upregulated (in red) or downregulated 
(in green). Genes that are related to hNPC identity, post mitotic neurons and synapse formation are 
highlighted. (E) Immunofluorescence staining of MAP2, TUBB3, FOXG1, and NEUN in plated neuron-
MC aggregates (scale bar = 200 um). (adapted from Srinivasan et al.) 
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3.4  Astrocytic Differentiation of hNPCs on VDP and LN 
HNPCs have the capability of differentiating into all cell types of the CNS including 
astrocytes. As such, AD- and NDC-hNPCs were differentiated into astrocytes using the 
commercially available Astrocyte Medium (ScienCell) with the three growth factors 
CNTF, BMP4, and NRG-1. Initially, these cells were differentiated on laminin coated 
plates for 50 days and assessed for their expression of astrocyte markers and functional 
characteristics. After at least 50 days, AD- and NDC-hNPC expressed the astrocyte 
markers GFAP and S100B as assessed through immunofluorescence (Figure 3-7B). Flow 
cytometry showed both AD- and NDC-astrocytes expressed S100B as well as the surface 
cell marker CD44 (Figure 3-7C). A characteristic of functionally mature astrocytes is 
their propensity to generate an inflammatory response within the CNS. To assess this, 
astrocytes were treated with lipopolysaccharide (LPS) for 24 hours with a saline control 
and media was collected. The level of IL-6, one of many possibly secreted cytokines, was 
measured using a Human IL-6 ELISA kit (Invitrogen). AD- and NDC-astrocytes both 
showed statistically significant higher levels of IL-6 secretion than hNPCs (Figure 3-7D). 
Additionally, astrocytes secrete Apolipoprotein E (ApoE), which has been identified as 
an important genetic risk factor in sporadic Alzheimer’s disease. To determine if 
astrocytes were producing ApoE, cells were cultured in serum-free media for 24 hours 
and supernatant was collected and subsequently concentrated.  Amount of ApoE was 
determined using a Human ApoE ELISA kit (Thermo Fisher) and normalized to total 
protein as measured using a Bradford assay. Astrocytes produced approximately 110 
ng/mg total protein (Figure 3-7E). Glutamate, an important neurotransmitter, can lead to 
neuron cytotoxicity in high concentrations. Astrocytes mediate the levels of glutamate 
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within the extracellular. Astrocytes differentiated on laminin were incubated in HBSS 
containing glutamate and samples were taken at 1 and 2 hours. The level of glutamate 
within the supernatant was used to determine if cells had taken up glutamate as expected. 
Astrocytes decreased the glutamate within the supernatant after 1 hour, however the level 
of glutamate within the supernatant increased after another hour albeit still below the 
initial concentration (Figure 3-7F).  
 
Figure 3-4: AD- and NDC-hNPC Derived Astrocytes on Laminin Coated Plates. (A) Representative 
phase contrast image of D50+ Astrocytes differentiated on laminin. (scale bar = 400 µm) (B) 
Immunofluorescence for GFAP and S100B expression in NDC and AD-Astrocytes. (scale bar = 400 µm) 
(C) Flow cytometry analysis for  CD44 and S100B expression in NDC and AD-Astrocytes. (mean ± 
S.E.M.) (D) IL-6 secretion following treatment with LPS in both NDC and AD-Astrocytes and hNPCs. 
(mean ± S.E.M.) (Student’s T-test, *p<1x10-5) (E) ApoE secretion normalized to total protein in Astrocytes 
and hNPCs. (mean ± S.E.M.) (F) Glutamate uptake in astrocytes measured at 1 and 2 hrs normalized to 
total protein. (mean± S.E.M.) 
 
Next AD(188)- and NDC(414)-hNPCs were differentiated into Astrocytes as described 
above on both VDP and laminin coated plates. AD- and NDC-astrocytes on both laminin 
and VDP appeared to have an immature morphology as there was an absence of star-like 
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projections from the cell bodies (Figure 3-8A). Immunofluorescent staining however did 
reveal expression of GFAP and S100B in astrocytes differentiated on both VDP and 
laminin (Figure 3-8C). AD- and NDC-hNPC derived astrocytes also showed expression 
of the markers CD44 and S100B through flow cytometry (Figure 3-8B). Additionally, 
these astrocytes were functionally characterized as described above for secretion of ApoE 
and IL-6. AD-astrocytes differentiated on laminin showed high levels of ApoE secretion. 
However, NDC-astrocytes on both substrates and AD-astrocytes on VDP showed lower 
amounts of ApoE within the supernatant (Figure 3-8D).  
 
Figure 3-5: AD- and NDC-hNPC Derived Astrocytes on VDP Coated Plates. (A) Representative phase 
contrast images of D90+ AD- and NDC-Astrocytes differentiated on VDP coated surface. (scale bar = 400 
um) (B) Flow cytometry analysis for CD44 and S100B expression in NDC and AD-Astrocytes. (mean ± 
S.E.M.) (C) Immunofluorescence for GFAP and S100B expression in NDC and AD-Astrocytes. (scale bar 
= 400 µm) (D) ApoE secretion normalized to total protein in Astrocytes and hNPCs. (mean ± S.E.M.) 
(Student’s T-test, *p<0.05) (E) IL-6 secretion following treatment with LPS in both NDC and AD-
Astrocytes differentiated on laminin and VDP and hNPCs. (mean ± S.E.M.) (Two-way ANOVA, *p<0.05, 
**p<0.001, ***p<0.00001)  
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Lastly, astrocytes on VDP and Ln were treated with LPS for 24 hours at varying 
concentrations, and inflammatory response through IL-6 secretion was measured. Both 
AD- and NDC-astrocytes had statistically significant higher levels of IL-6 as compared to 
hNPCs, however it appears that only in astrocytes differentiated on VDP was there a dose 
response. AD- and NDC-astrocytes differentiated on both substrates did not demonstrate 
an uptake of glutamate (data not shown). 
Finally 160-hNPCs, another AD patient-derived cell line, was differentiated into 
astrocytes on both laminin and VDP. After 80 days within a commercial differentiation 
media these cells showed a morphology expected of astrocytes with fibrous star-like 
projections (Figure 3-6A). Additionally, flow cytometry analysis demonstrated 
expression of the surface marker CD44 as well as the mature astrocyte marker, S100B 
(Figure 3-6B). Immunofluorescent microscopy also demonstrated expression of S100B in 
addition GFAP was shown to be expressed in astrocytes on both laminin and VDP 
(Figure 3-6C). Next, it was investigated whether these cells performed functions 
physiologically typical of astrocytes. Firstly, it was confirmed that astrocytes secreted the 
protein ApoE through an ELISA kit (Figure3-6D). To determine if 160-astrocytes would 
simulate an inflammatory response cells were treated with LPS as previously described. 
160-astrocytes showed increased levels of IL-6 secretion in the presence of LPS. Finally, 
cells differentiated from 160-hNPCs were shown to uptake glutamate after both 1 and 2 
hours, however the result was not statistically significant for laminin or VDP.  
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Figure 3-6: 160-hNPC Derived Astrocytes on VDP Coated Plates. (A) Representative phase contrast 
images of D80+ 160-Astrocytes differentiated on a VDP coated surface. (scale bar = 400 um) (B) Flow 
cytometry analysis for CD44 and S100B expression in 160-Astrocytes. (C) Immunofluorescence for GFAP 
and S100B expression in 160-Astrocytes. (scale bar = 200 µm) (D) ApoE secretion normalized to total 
protein in Astrocytes and hNPCs. (mean ± S.E.M.) (Student’s T-test, *p<0.05) (E) IL-6 secretion following 
treatment with LPS in 160-Astrocytes differentiated on laminin and VDP and hNPCs. (mean ± S.E.M.) 
(Two-way ANOVA, *p<0.05) (F) Glutamate uptake in 160-Astrocytes at two starting concentrations 
normalized to total protein. (mean ± S.E.M.) 
 
 
* 
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4.  DISCUSSION 
The widespread implementation of hNPCs in both translational and clinical applications 
requires the development of a completely defined and scalable biomanufacturing 
platform. Previously, a synthetic peptide was engineered from the cell binding domain of 
Vitronectin, an extracellular matrix protein (ECMP), and shown to be capable of 
supporting the long-term expansion and differentiation of hNPCs on 2D tissue culture 
treated plates. Additionally, microcarriers, small polystyrene beads, coated in this 
synthetic peptide were able to scale up the culture of hNPCs and allow for their long-term 
expansion in greater numbers than on 2D surfaces. While also, allowing for the 
differentiation of hNPCs into neurons expressing several cortical and neurotransmitter 
markers. 
VDP coated MC were integrated into a rotating wall vessel bioreactor culture system and 
allowed for a 10-fold increase in the number of viable hNPCs following 6-8 days of 
expansion. HNPCs cultured within the bioreactor continued to highly express the markers 
SOX1, SOX2, and Nestin. Utilizing all four 55 mL vessels, would allow for the 
generation of nearly 1 billion viable hNPCs for use in drug screening and disease 
modeling.  
This bioreactor culture system was also shown to support the differentiation of hNPCs 
into mature neurons expressing several neuronal, cortical, and neurotransmitter markers. 
This system could produce neurons on a much larger scale than typical 2D culture 
methods. Additionally, these neurons were able to remain as aggregates on VDP-MC for 
greater than 30 days. This platform will be useful to the further implementation of hiPSC-
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derived neurons in the development of drugs and new treatment strategies for 
neurodegenerative disease such as Alzheimer’s and ALS. 
VDP was able to support the differentiation of hNPCs into cells expressing markers 
typical of astrocytes. Also, astrocytes differentiated on VDP demonstrated a release of 
inflammatory cytokines, secretion of apolipoprotein E, as well as glutamate uptake. 
While initial differentiations may have shown immature phenotypes this was consistent 
across substrates and cell lines. Further work will be needed to optimize the 
differentiation of hNPCs into astrocytes on VDP.  
Current biomanufacturing systems fail to produce physiologically relevant cells for use in 
disease modeling, cell-based therapies and clinical drug development. The culture system 
described here addresses the primary issues facing development of such a process. This 
CNS-specific cell culture system eliminates the use of reagents such as laminin which are 
subject to significant batch-to-batch variations. Additionally, it produces cells of a 
neuronal phenotype in numbers greater than demonstrated previously. It is also possible 
that this 3D suspension culture could be adapted to other adherent cell types. This system 
will be of particular value to both clinicians and researchers investigating 
neurodegenerative disease.   
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5.  FUTURE WORK  
The integrated biomanufacturing platform developed within this study will allow for the 
chemically defined large scale expansion and differentiation of hNPCs. This technology 
could support the development of cell therapies, and importantly provide a better 
platform for modeling and studying diseases such as Alzheimer’s Disease or amyotrophic 
lateral sclerosis. Currently, this platform has successfully demonstrated mature neurons. 
It will be of interest to expand this protocol to allow for the differentiation of hNPCs into 
more specific neuronal subtypes within the central nervous system. As well as, use this 
platform for the generation of functionally mature neurons derived from patients who 
suffer from neurodegenerative disease. This will be necessary to develop small molecule 
therapies or understand the mechanisms of the various diseases impacting the CNS. 
Vitronectin derived peptide, a chemically defined substrate, has been shown to support 
the differentiation of hNPCs into Astrocytes. However, given the inconsistent phenotype 
of these cells it will be necessary to optimize their differentiation on VDP. It will also be 
of interest to integrate astrocytes within the biomanufacturing platform described herein 
for their large scale expansion and differentiation. Many neurodegenerative diseases such 
as ALS, exhibit non-autonomous cell toxicity and require more complex models of the 
disease capable of incorporating these features.  
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APPENDIX A 
 FORWARD AND REVERSE PRIMERS USED FOR RT-QPCR 
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Gene Forward Reverse 
 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
NESTIN CGCACCTCAAGATGTCCCTC CAGCTTGGGGTCCTGAAAGC 
SOX2 TTTGTCGGAGACGGAGAAGC CCCGCTCGCCATGCTATT 
MAPT AGGGGGCTGATGGTAAAACG TTGCTTAGTCGCAGAGCTGG 
NCAM GATGCGACCATCCACCTCAA CCAGAGTCTTTTCTTCGCTGC 
RBFOX3 TGGGACGATCGTAGAGGGAC CTTCCAGCCGTTGGTGTAGG 
TUBB3 GAGGGGCATCTCTTGAGAACAA CCCAGAACTGTGGACGCCT 
LHX9 TACCACTCTAGAGGCAGCCA GGCATGCCCGCGTCG 
EMX1 GAGACGCAGGTGAAGGTGTG CACCGGTTGATGTGATGGGA 
EMX2 ATCCGTCCACCTTCTACCCC ACCATACTTTTACCTTGGAAGCG 
ASCL1 TCCCCCAACTACTCCAACGA GCGATCACCCTGCTTCCAAA 
GFAP AACCTGCAGATTCGAGGGGG GGCGGCGTTCCATTTACAATC 
 
Table 2: Forward and Reverse Primers Used for RT-qPCR 
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APPENDIX B 
ANTIBODIES USED FOR IMMUNOFLUORESCENCE AND FLOW CYTOMETRY 
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Antibody Vendor Catalog Number Concentration Used 
Goat anti-SOX2 Santa Cruz SC-17320 1:50 
Mouse anti-SOX1 BD BD 56749 1:50 
Mouse anti-Nestin BD BD 560341 1:50 
Mouse anti-B3T Fitzgerald 10R-T136A 1:1000 
Rabbit anti-GFAP Millipore AB360 1:500 
Rabbit anti-FOXG1 Abcam AB18259 1:500 
Mouse anti-S100B Sigma S2532 1:500 
Rabbit anti-MAP2 Millipore AB5622 1:500 
Alexa-647 Mouse 
anti-SOX2 
BD BD 560294 1:10 
Alexa-647 Mouse 
anti-Nestin 
BD BD 560341 1:10 
PerCP-Cy5.5 
Mouse anti-SOX1 
BD BD 561549 1:10 
Alexa-647 Donkey 
anti-Mouse 
Life Technologies A31571 1:200 
Alexa-647 Donkey 
anti-Goat 
Life Technologies A-21447  1:200 
Alexa-488 Donkey 
anti-Mouse 
Life Technologies A-21202 1:200 
Alexa-488 Donkey 
anti-Rabbit 
Life Technologies A-21206 1:200 
Table 3: Antibodies Used for IF and Flow Cytometry  
